58 results about "C-Met inhibitor" patented technology

The present invention provides a compound of Formula Ior a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and / or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and / or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

The invention discloses a pyridino five-membered heterocyclic derivative or a pharmaceutically acceptable salt of the pyridino five-membered heterocyclic derivative, a structure of which is shown in general formula I. The invention also relates to a preparation method and applications of the pyridino five-membered heterocyclic derivative or the pharmaceutically acceptable salt of the pyridino five-membered heterocyclic derivative in the preparation of drugs used as a c-Met inhibitor.

The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.

The present invention relates to a heterocyclic pyridone compound represented by General Formula (I), where the heterocyclic pyridone compound is used as a tyrosine kinase inhibitor, and particularly a c-Met inhibitor. The present invention also relates to intermediates for preparing heterocyclic pyridone compound and a preparation method. The present invention further relates to a pharmaceutical composition containing the heterocyclic pyridone compound as an active ingredient, and a use of the pharmaceutical composition in treatment of diseases associated with tyrosine kinase c-Met, especially cancer associated with c-Met, as a medicament.

The invention relates to (1,2,4)-triazolo-(4,3-b) (1,2,4)-triazine compounds which are of a novel structure and are shown in a formula (I) or formula (II), and a pharmaceutical salt, a prodrug, a hydrate or a solvate thereof, a preparation method of the compounds, a pharmaceutical composition containing the treatment effective dose of the compound and an application of the compound as a protein tyrosine kinase inhibitor, especially as a c-Met inhibitor, in the preparation of medicaments for preventing and / or treating c-Met abnormality-related diseases.

The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.

This invention relates to novel fused quinazoline derivatives of Formula I as c-Met inhibitors, their synthesis and uses for treating c-Met mediated disorders.

A method of preventing and / or treating a cancer including co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor, and a kit comprising a pharmaceutical composition comprising a c-Met inhibitor, and a pharmaceutical composition comprising a beta-catenin inhibitor packaged together.

The invention relates to a 4-phenoxyquinoline and alpha-acyloxyamide compound I. The 4-phenoxyquinoline and alpha-acyloxyamide compound I is taken as a protein tyrosine kinase (PTK) inhibitor, particularly a c-Met inhibitor. The invention also relates to a preparation method of the compound; the invention further relates to application of the 4-phenoxyquinoline and alpha-acyloxyamide compound I as a drug to the treatment of PTK c-Met related diseases, particularly c-Met related cancer.

Provided are [1,2,4]triazol[4,3-a]pyridine derivatives as shown in the general formula (I), a preparation method therefor, and a pharmaceutical composition containing the derivative, wherein the pharmaceutical composition is used as a therapeutic agent, and especially used as a c-Met inhibitor and an immunosuppressant. Each substituent in the general formula (I) is the same as that defined in the specification.